Our management team brings a wealth of business, technical and management experience to the company. In many cases, spanning decades working across a number of well-known and highly successful Life Sciences companies. Under their leadership, Sphere Fluidics has progressed from a promising start-up into an internationally-recognised tools provider firm holding over 50 patents. We have evolved our strategy from providing biochips and specialist chemicals to commercialising high value single cell analysis systems that enable therapeutic discovery. This team has identified addressable markets of over £1 billion for our technology.
Dr Frank F. Craig MBA
CEO and Director
Dr Craig has around 20 years of international, general management experience gained from GlaxoSmithKline, Amersham Biosciences (as a Vice-President of R&D and which later merged to form GE Healthcare Life Sciences), and several start-up firms. He was responsible for driving the product development of the widely known and utilised biological tool, Green Fluorescent Protein (first identified by the 2008 Nobel Prize Winners for Chemistry), as well as many other cell-based products, systems and services for the Life Sciences industry.
Frank was a co-Founder and Vice-President of Aurora Biosciences (San Diego, USA), which had a peak market cap. of £1.8 billion and was acquired by Vertex Pharmaceuticals for £420 million. He was also a co-Founder and CEO of Smart Holograms (Cambridge, UK), which was previously named as the UK’s Fastest Growing Company. Frank has raised around £30 million in Angel and Venture Capital investment, £25 million via an IPO on NASDAQ and has delivered many commercial partnerships with global Life Sciences firms, resulting in recorded deal values of £180 million. He has been a Board Director of Smart Holograms and TekCel (Hopkinton, USA), and helped form Sphere Fluidics before becoming its CEO in May 2010. He is now also President of Sphere Fluidics Incorporated. He has a PhD in Cell Biology and Microbiology from Glasgow University and an MBA from Warwick Business School.
Dr Rob Marchmont
Dr Marchmont brings more than 25 years of experience in privately-owned and publicly-traded Life Sciences companies to Sphere Fluidics. He has a proven track record in business development, technical selling and strategic marketing. Previously, Rob has held various senior commercial roles, such as the General Manager EMEA at NanoInk Incorporated, CEO of TotalLab, European Business Director for Protein Forest Inc. and Global Marketing Director for GE Healthcare’s Life Sciences Division (where he was responsible for strategic marketing and product portfolio development for its Protein Detection and Analysis business segment).
Dr Marchmont has a BSc in Biochemistry and PhD in Membrane Biochemistry from the University of Manchester. He also carried out 3 years’ post-doctoral research in targeted, monoclonal antibody research at the Paterson Institute for Cancer Research, UK.
Mr John Mayfield MBA
John brings more than 25 years of experience in finance and accounting in the UK and internationally at businesses ranging from early-stage to large and listed corporates. At Sphere Fluidics, John is responsible for leading accounting, reporting, financial and cash management. He trained in practice at PKF, and later moved into industry with UBS and Time Warner. John has worked for KPMG, led finance at multi-site operations at CDC and ED&F Man in the Americas and is fluent in Spanish. More recently, he has been playing a lead role in the fundraising, growth, process improvement and restructuring at SME businesses primarily in the Technology and Life Sciences sectors. John ACCA and CIMA qualified with an MBA from Cranfield School of Management.
Dr Marian Rehak
Director of Research and Development
Dr Rehak is responsible for the management of all Research and Development (R&D) and Manufacturing activities at Sphere Fluidics. He has a strong research background and more than 20 years’ experience in industrial and academic R&D environments.
Marian has led several R&D teams to deliver novel platforms for application within the Life Science, drug discovery and the diagnostic sectors. Following a series of post-doctoral research positions at the University of Tokyo, the Weizmann Institute and the University of Cambridge, Marian held a number of R&D related roles at several biotechnology companies, including Akubio, Unipath and DxTech, in addition to a leading technology development consultancy. During these engagements, Marian, as a leader and a member of Senior R&D teams, was responsible for R&D and the manufacturing of point-of-care and Life Science instrumentation, over-the-counter diagnostics, fluidics and biosensor chip assemblies.
Mr Craig Cardella BSc
Sales and Marketing Director, North America
Craig Cardella is the North America Sales and Marketing Director of Sphere Fluidics Inc, the newly formed subsidiary of Sphere Fluidics Ltd. The company is strategically based in Trenton, New Jersey.
Craig brings with him over 20 years of laboratory and industry experience with a proven track record in Applications, Sales and Sales Management. He has been won numerous awards and gained high recognition in sales and support over the course of his career.
Craig started out working in an HTS and robotics lab at Boehringer Ingelheim gaining invaluable experience and insight in high throughput screening, automating bench assays, creating robotic systems and providing support for the company’s cell culture facility.
Craig’s love for automation and robotics helped him transition into the commercial world. He has held various roles of increasing responsibility ranging from Applications Support to Sales Executive with such companies as Perkin-Elmer, Thermo-Electron Lab Automation (now Thermo-Fisher), Matrical Bioscience (now Brooks Automation) and Caliper Life Sciences (now Perkin-Elmer). Craig most recently held the position of co-Founder and President of Scienion US. He established the latter US subsidiary and offices and managed a team of sales, service and laboratory personnel. Craig has A BSc in Biochemistry from the University of Connecticut.